Arkansas State will enroll its first DVM class this fall, opening the state's first vet college in Jonesboro and shortening the commute for Memphis‑area students.

Ann Arbor-based Esperion agreed to be acquired by ARCHIMED for $3.16 per share plus potential milestone payments, valuing the firm up to $1.1 billion.

Avalyn’s Nasdaq debut raised about $300M and the stock jumped 64% to close at $29.49 as the company advances inhaled therapies for pulmonary fibrosis.

Richard and Gayle Landuyt pledged more than $20 million to rename the University of Illinois entrepreneurship hub and build a Chicago presence to speed startups. The gift will fund leadership, prizes and programming across campus and downtown.

Alphabet posted $62.6B in Q1 net income as Google Cloud grew 63% and backlog swelled above $460B, sending Bay Area AI investments into overdrive.

A West Health–Gallup poll finds many Americans consult AI for health questions — and roughly 14 million say AI advice led them to skip care. Stanford’s chief data scientist weighs in.

PocketOS founder says a Cursor agent running Anthropic’s Claude wiped the company’s production database and volume backups in nine seconds; Railway says it restored the data.

Biogen beat Q1 estimates as Leqembi sales surged 74% to $168M, but the company trimmed full‑year EPS after booking deal‑related charges tied to the Apellis purchase.

Monthly DNA records from Station ALOHA show seasonal niche partitioning in more than 60% of ocean microbes, a pattern that persists down to deep sea and helps sustain food webs.

J. Craig Venter, the La Jolla genomics pioneer who helped map the human genome and later built synthetic cells, died April 29 at 79.

Charlotte‑based Truist awarded Infosys a more‑than‑$500M contract to build and run an offshore tech hub in India, a deal that could reshape where the bank’s tech work lives.

The Minnesota Senate voted unanimously to ban AI "nudification" tools that make nonconsensual nude images, creating civil remedies and steep penalties for operators. The bill now heads to the governor.

Texas Biomed researchers are developing a flu vaccine that could protect for years by targeting stable viral parts; animal studies are the next step.